HEALTH ALERT—NOVEL INFLUENZA A H1N1 (SWINE) VIRUS
SURVEILLANCE, TESTING, REPORTING, ANTIVIRAL TREATMENT AND
CHEMOPROPHYLAXIS, AND INFECTION CONTROL PRECAUTIONS

Tuesday May 12, 2009

✓ Information and Instructions continue to change
✓ Future updates will NOT necessarily be sent via fax
✓ Check our website for updates (www.sfcdcp.org/swineflu.html)

Situational Update (as of 5/12/09)

As of May 12, CDC reports 3009 lab-confirmed cases in 45 states and 3 deaths in persons with underlying medical conditions. As of May 11, California reports 193 lab-confirmed and 202 probable cases from 26 counties. San Francisco has 5 confirmed and 1 probable case.

Nearly all cases in the USA have been mild, with clinical presentation and outcomes similar to seasonal influenza. In California, fever was present in 94% of cases, cough in 87%, sore throat in 75%, diarrhea in 27%, and vomiting in 29%. Twenty-two have been hospitalized. The median age is 17 years and 93% of cases occurred in persons from 1 to 49 years of age. However, the Novel Influenza A H1N1 (swine) influenza virus is new and its ultimate clinical severity and age groups affected are not yet known.

Now that the Novel influenza A H1N1 (swine) virus is known to be established in San Francisco and the region, the focus of surveillance has shifted away from detecting every case. The current goals are to:
(1) Determine whether this virus is causing severe disease,
(2) Detect cases in settings with higher risk of transmission (e.g., health care and institutional settings), and
(3) Identify clusters of cases.

Actions Requested of All Clinicians (updated 5/12/09)

1. Submit respiratory specimens only from the following patients for PCR testing by the Public Laboratory System (specimens not meeting these criteria will not be tested):
   a) Patients with influenza-like illness OR
   b) Patients with influenza A as determined by a rapid diagnostic test

   AND who also meet at least one of the following criteria:
   ♦ Hospitalized (if info is available specific criteria will be “hospitalized for > 24 hours”)
   ♦ Direct health care providers
   ♦ Live or work in an institutional setting (e.g., correctional facility, long term care facility); the first case in a facility will be tested but not all subsequent cases
   ♦ Are part of an outbreak or cluster of cases

   For specimen collection/submission instructions go to: www.sfcdcp.org/swinefluforproviders.html.

Continues on next page …
Notes & Definitions (updated 5/12/09)

- **Influenza-like illness** is defined as fever (>37.8°C or 100°F) and either cough or sore throat.

- **Close contact** to an ill person is defined as having cared for or lived with an ill person, or having been in a setting where there was a high likelihood of contact with respiratory droplets and/or body fluids of an ill person. Examples of close contact include kissing or embracing, sharing eating or drinking utensils, physical examination, or any other contact between persons likely to result in exposure to respiratory droplets. Close contact typically does not include activities such as walking by an infected person or sitting across from a symptomatic patient in a waiting room or office.

- **Cluster of cases** is defined as several patients with influenza-like illness, not from the same household, who are grouped together in time and space.

- **Suspected case of novel influenza A H1N1 (swine) virus** is defined as a person with influenza-like illness with onset within 7 days of close contact with a probable/confirmed case of novel influenza A H1N1 (swine) virus.

**Antiviral Treatment for Novel Influenza A H1N1 (Swine) Virus** (5/12/09)

Most cases in the USA have been mild and have not required antiviral treatment. Therefore antiviral treatment is not specifically indicated unless cases of swine influenza (including suspected cases) are

1) hospitalized OR

2) at high risk for complications of influenza. People at high risk for complications include:

- Children age 4 years and younger, especially children younger than age 2 years
- Adults age 65 and over
- Pregnant women
- Residents of nursing homes and other chronic-care facilities.

- Persons with the following conditions:
  - chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematological (including sickle cell disease), or metabolic disorders (including diabetes);
  - immunosuppression, including that caused by medications or by HIV infection;
  - Any condition (e.g., cognitive dysfunction, spinal cord injuries, severe seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.

- Persons younger than 19 years of age and receiving long-term aspirin therapy.

**Actions Requested of All Clinicians** (updated 5/12/09)

2. **Report** to SFDPH Disease Control (415-554-2830): Fatal or severe (requiring ICU) cases of undiagnosed influenza-like illness, suspected or confirmed influenza A or; outbreaks/clusters of suspected swine flu cases.

3. **Treat** swine flu cases (including suspect cases) that are hospitalized and/or at high risk for complications.

4. **Give chemoprophylaxis** to certain close contacts of cases, as described below.

5. **Implement** infection control precautions as described below.

6. **Provide** guidance about home care of persons with influenza. SFDPH guidance (including a 2 page document and a 61 page handbook) is available at [http://www.sfcdcp.org/H1N1ill.html](http://www.sfcdcp.org/H1N1ill.html).
Other patients may receive antiviral treatment at the discretion of their treating clinician. However please exercise prudent judgment in prescribing antiviral medicines for patients with mild influenza-like illness who are not at high risk for complications of influenza.

Treatment is for 5 days and, if possible, should be initiated within 48 hours of symptom onset.

**Antiviral Post-Exposure Chemoprophylaxis for Novel Flu A H1N1 (Swine) Virus (5/12/09)**

Antiviral chemoprophylaxis is **recommended** for:

1. Employees and residents of a nursing home or other long-term care facilities experiencing an outbreak of novel influenza A H1N1 (swine) virus.
2. Health care workers who were not using personal protective equipment during close contact with a confirmed or probable case of novel influenza A H1N1 (swine) virus during the infectious period of that case (from 1 day before until 7 days after symptoms began).

Antiviral chemoprophylaxis can be **considered** for:

1. Household or institutional* close contacts of a confirmed/probable or suspect case of novel influenza A H1N1 (swine) virus, who are at high risk for complications of influenza**.
2. Patients at high risk for complications who have had close contact with an infectious health care worker with confirmed or probable case of novel influenza A H1N1 (swine) virus.

* Institutions are defined as facilities with household-like living arrangements such as group homes, homeless shelters, jails, long-term care facilities.

**Persons at high risk for complications include: children age 4 years and younger, especially children under age 2 years, adults age 65 and over, pregnant women, residents of nursing homes or other long-term care facilities, persons with chronic medical conditions including pulmonary, cardiovascular, renal, hepatic, hematologic, and metabolic disorders, persons with immunosuppression or compromised ability to handle respiratory secretions, and persons less than age 19 years on chronic aspirin therapy.

Duration of antiviral chemoprophylaxis post-exposure is 10 days after the last known exposure to an ill confirmed or probable case. Post-exposure prophylaxis is not necessary if the exposure occurred more than 7 days earlier.

Duration of antiviral chemoprophylaxis for outbreaks is for a minimum of two weeks. If new cases continue to appear duration may be extended.

**Selection of Antiviral Drugs for Seasonal or Swine Influenza (5/12/09)**

Selection of antiviral drugs for treatment or chemoprophylaxis of influenza depends upon:

1) Which strains of influenza are circulating in the community;
2) Strain-specific resistance to antiviral drugs; and
3) The ability of laboratory testing to identify the specific strain infecting a patient

**Circulating Strains.** Seasonal influenza infections are still occurring in San Francisco and in California. Circulating human strains include influenza A (H1N1 and H3N2 strains), and influenza B. Novel influenza A H1N1 (swine) virus is also present in our community.

**Strain-Specific Resistance.** In 2008-09, seasonal H1N1 influenza A was found to be resistant to oseltamivir, but sensitive to zanamivir and the adamantane drugs rimantadine and amantadine. However novel influenza A H1N1
(swine) virus is sensitive to oseltamivir and zanamivir but resistant to the adamantanes. The adamantanes are not active against influenza B strains. See Table 1.

Table 1: Antiviral Resistance 2008-2009, US Influenza Isolates

<table>
<thead>
<tr>
<th></th>
<th>Zanamivir</th>
<th>Oseltamivir</th>
<th>Adamantanes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza A H1N1 (Swine)</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>Influenza A H1N1 (Seasonal)</td>
<td>S</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>Influenza A H3N2</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>Influenza B</td>
<td>S</td>
<td>S</td>
<td>Not active</td>
</tr>
</tbody>
</table>

Laboratory Test Results

Rapid influenza antigen tests are widely available to clinicians and are often used to help guide initial therapy. Test accuracy can be problematic with rapid antigen tests, with sensitivity and specificity in the 60-80% range compared to viral culture. Thus false positive and false negative rapid tests are common and rapid diagnostic test results should be confirmed with RT-PCR or viral culture when available.

Some rapid tests can distinguish between influenza A and B virus types, while others cannot. For more information on rapid influenza tests see: http://www.cdc.gov/flu/professionals/diagnosis/rapidlab.htm.

Distinguishing between influenza A subtypes H1N1 and H3N2, or between novel influenza A H1N1 (swine) virus and seasonal influenza A H1N1 subtypes, requires specialized techniques not available at most clinical laboratories. Thus clinicians typically must select an antiviral drug based on rapid diagnostic tests, or clinical presentation alone.

Recommendations

Table 2 provides recommendations based on results of rapid diagnostic testing. All strains are susceptible to zanamivir, therefore, for empirical treatment, it is a practical single-drug option. Combination treatment with oseltamivir plus rimantadine** is an acceptable alternative, and might be necessary for patients that cannot receive zanamivir (e.g. those age less than 7 years, or with chronic underlying airway disease, or who cannot use the zanamivir inhalation device).

Table 2: Recommended antiviral drug based on results of rapid diagnostic tests*

<table>
<thead>
<tr>
<th>Rapid diagnostic test result</th>
<th>Treatment‡ or chemoprophylaxis medication(s)</th>
<th>Single drug option</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done or negative, but clinical suspicion for flu</td>
<td>Zanamivir</td>
<td>Oseltamivir + Rimantadine**</td>
<td></td>
</tr>
<tr>
<td>Positive: Influenza A</td>
<td>Zanamivir</td>
<td>Oseltamivir + Rimantadine**</td>
<td></td>
</tr>
<tr>
<td>Positive: Cannot distinguish Influenza A vs. B</td>
<td>Zanamivir</td>
<td>Oseltamivir + Rimantadine**</td>
<td></td>
</tr>
<tr>
<td>Positive: Influenza B</td>
<td>Oseltamivir or Zanamivir</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

*Modified from Table in CDC Health Advisory of Dec 19, 2008 and CDC Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and their Close Contacts (www.cdc.gov/h1n1flu/recommendations.htm).

** Amantadine can be substituted for rimantadine but has increased risk of adverse events. Human data are lacking to support the benefits of combination antiviral treatment of influenza; however, these interim recommendations are intended to assist clinicians treating patients who might be infected with oseltamivir-resistant human influenza A (H1N1) virus.

Categories of urgency levels
Health Alert: conveys the highest level of importance; warrants immediate action or attention
Health Advisory: provides important information for a specific incident or situation; may not require immediate action
Health Update: provides updated information regarding an incident or situation; unlikely to require immediate action
Antiviral dosing recommendations for novel influenza A H1N1 (swine) virus infection in adults and children age 1 year and older are the same as those recommended for seasonal influenza. Oseltamivir recently received FDA approval under an Emergency Use Authorization. For dosing information for children less than 1 year see: [www.cdc.gov/swineflu/childrentreatment.htm](http://www.cdc.gov/swineflu/childrentreatment.htm).

**Infection Control Precautions for Novel Influenza A H1N1 (Swine) Virus** (Updated 5/4/09)

All healthcare facilities should adopt, at a minimum, the following measures:

- Place signs at entryway and in all patient areas instructing ALL PERSONS to cover their mouth and nose when they cough or sneeze and to wash hands or use waterless hand cleanser after coughing or sneezing.
- Instruct all persons to cover the mouth/nose with a tissue when coughing or sneezing. Throw tissue in the trash after use. If tissue is not available then use an elbow rather than hands. Wash hands or use waterless hand sanitizer after contact with respiratory secretions.
- Request all persons with fever or cough to wear a surgical mask.
- Provide masks, tissues and waterless hand cleanser in all patient areas and entryways to patient areas;
- Isolate patients with influenza-like illness as soon as possible, ideally in a private exam room or at a distance of at least 3 feet from others.
- Staff entering the exam room of a patient with influenza-like illness should wear a surgical mask until an infectious cause of illness is ruled out and should wash their hands or use waterless hand cleanser before and after interactions with the patient.
- Persons with influenza-like illness should be instructed to stay at home until they have fully recovered.

Note: Respiratory Hygiene/Cough Etiquette is now a component of Standard Precautions. To limit disease transmission year round, health care providers should implement respiratory hygiene/cough etiquette and hand hygiene procedures in the health care setting and, when possible, in the community.

Note: Please refer to CAL-OSHA for employee health and safety regulations.

**Information for International Travelers** (updated 5/4/09)

CDC advises (see: [www.cdc.gov/travel/contentSwineFluTravel.aspx](http://www.cdc.gov/travel/contentSwineFluTravel.aspx)):

a. Avoid all non-essential travel to Mexico;

b. Antiviral chemoprophylaxis with oseltamivir or zanamivir may be considered for travelers to Mexico who are at high risk for complications of influenza; and

c. Seasonal flu vaccine is recommended for all travelers.

**How SFDPH Performs Testing for Novel Influenza A H1N1 (Swine) Virus** (5/1/09)

The SFDPH Public Health Lab first determines whether the sample is positive for Influenza Type A. (Influenza Type A is a general category of Influenza and includes both human and swine viruses.)

Specimens positive for Influenza Type A are tested by PCR for the Human H1 or the Human H3 virus subtype.

- Those positive for either Human H1 or Human H3 are reported as such.

- Those negative for both Human H1 and Human H3 are considered “untypable” and, if the case meets clinical criteria, a probable case of novel influenza A H1N1 (swine) Virus. (This is because the novel influenza A H1N1 (swine) virus is NOT detectable by our PCR test when it is sub-typed by PCR.) These
specimens are submitted to the California State Laboratory for confirmation and final determination of novel influenza A H1N1 (swine) virus.

**Adverse Events from Influenza Antiviral Medications (4/29/09)**

For information about influenza antiviral medications, including contraindications and adverse effects, go to
- [www.cdc.gov/flu/professionals/antivirals/side-effects.htm](http://www.cdc.gov/flu/professionals/antivirals/side-effects.htm)
- [www.cdc.gov/mmwr/preview/mmwrhtml/rr5707a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5707a1.htm)

Please report adverse events from influenza antivirals to the FDA: [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

**Local Resources for Clinicians (5/12/09)**

SFDPH website:
- Swine flu page: [www.sfcdcp.org/swineflu.html](http://www.sfcdcp.org/swineflu.html)
- Guidance on home care for people ill with the flu including a 2 page document and/or a 61 page booklet: [http://www.sfcdcp.org/H1N1ill.html](http://www.sfcdcp.org/H1N1ill.html)
  To order 61 page Flu Home Care Guide: [http://www.sfcdcp.org/materials_request.html](http://www.sfcdcp.org/materials_request.html)

Hospital-based clinicians should call their hospital’s Swine Flu Point of Contact. Most hospitals designated an Infection Control Professional as their Swine Flu Point of Contact.

If the above resources do not provide adequate information:
- For more urgent issues clinicians may call 415-554-2830 and request the Clinician Consultation team
- Non-urgent issues may be sent via email to: communicable_disease_information_branch.dph@sfdph.org